



Description générale

Dactinomycin is an antineoplastic agent that inhibits DNA, RNA and protein synthesis. It is used in treatment protocols for many cancers including gestational trophoblastic neoplasia, rhabdomyosarcoma and Wilms tumour (nephroblastoma).

INN	Dactinomycin
Codes ATC	L01DA01
Type de médicament	Chemical agent
Historique des statuts LME	<p>Ajouté pour la première fois en 1984 (TRS 722) pour Malignant trophoblastic neoplasms of placenta</p> <p>Ajouté en 1984 (TRS 722) pour Malignant neoplasms of kidney, except renal pelvis</p> <p>Ajouté en 1984 (TRS 722) pour Rhabdomyosarcoma primary site</p> <p>Ajouté en 1984 (TRS 722) pour Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Retiré en 2015 (TRS 994) pour Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Ajouté en 2021 (TRS 1035) pour Ewing sarcoma of bone and articular cartilage of unspecified sites</p>
Wikipédia	Dactinomycin 
DrugBank	Dactinomycin 

Recommandations

Section Cytotoxic medicines

Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

Malignant trophoblastic neoplasms of placenta

Rhabdomyosarcoma primary site

Malignant neoplasms of kidney, except renal pelvis

Unspecified malignant neoplasms of ill-defined or unspecified sites

Ewing sarcoma of bone and articular cartilage of unspecified sites

